Regeneus stem cell therapy reaches Melbourne
Regeneus (ASX:RGS) has announced that its stem cell therapy HiQCell is now available in Melbourne for the first time.
The company has established a new cell-processing laboratory at Linley Clinic Private Hospital in collaboration with sports and exercise physician Dr Philip Bloom at Bounce Health Group.
HiQCell is an autologous point-of-care therapy for musculoskeletal conditions including osteoarthritis. It is designed to reduce inflammation and repair damaged tissue.
The therapy is derived from a patient’s adipose (fat) tissue, as extracted by a treating medico. Regeneus staff then use the tissue to prepare a cell therapy in-clinic.
The therapy has to date been used in over 800 joints from more than 350 people in New South Wales and Queensland, but this launch marks a debut in Victoria.
Regeneus is also developing Cryoshot, an allogeneic cell therapy for joint conditions in animals, and has a human product based on the same technology in preclinical trials.
The company recently concluded a $10.5 million IPO, the first Australian biotech float since 2011.
Regeneus (ASX:RGS) shares grew 4% on Wednesday to $0.255 after the debut was announced.
Relapse risk predicted for little-known autoimmune disease
Often referred to as a cousin of MS due to shared symptoms, MOGAD is a little-known autoimmune...
Perinatal HIV transmission may lead to cognitive deficits
Perinatal transmission of HIV to newborns is associated with serious cognitive deficits as...
Gene editing could make quolls resistant to cane toad toxin
Scientists from Colossal Biosciences and The University of Melbourne have introduced genetic...
